首页 > 最新文献

Arab Journal of Urology最新文献

英文 中文
Author self-citations in the urology literature. 泌尿外科文献中的作者自我引用。
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-03-30 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2056976
Vaibhav Aggarwal

Objective: We aimed to determine the diachronous self-citation rate and the various article characteristics which can influence the rate and percentage of diachronous author self-citations using papers published in high-rank urology journals.

Methods: We included all papers (N = 327 articles) published between January 2015 to April 2015 in the European Urology, The Journal of Urology and the BJU International. We determined author self-citations using the Scopus database and used negative binomial regression to determine which article characteristics affect self-citations.

Results: 262 articles (80.2%) contained at least one self-citation.The mean number and percentage of author self-citations were 6.5 and 14.2 respectively. Adjusted analysis showed that the experimental/animal study design and the number of authors were significantly associated with both the number (IRR = 2.12, P = 0.011; IRR = 1.03, P = 0.002) and percentage of author self-citations (IRR = 2.95, P = 0.003; IRR = 1.03, P = 0.012). The number of citations in the Scopus and publication in European Urology were significantly associated with only the number of author self-citations.

Conclusion: Diachronous author self-citation rate in urology is higher compared to general medical literature but similar to other surgical subspecialties. It may depend on the study design and the number of authors in the paper. For a more comprehensive evaluation, future studies should look at the context in which self-citations were made.

目的:研究泌尿外科高水平期刊论文作者的非时性自引率及影响作者非时性自引率和百分比的文献特征。方法:纳入2015年1月至2015年4月在欧洲泌尿外科、泌尿外科杂志和BJU国际杂志上发表的所有论文(N = 327篇)。我们使用Scopus数据库来确定作者的自引,并使用负二项回归来确定哪些文章特征会影响自引。结果:262篇(80.2%)文献至少包含1条自引。作者平均自引次数为6.5次,自引百分比为14.2次。调整后的分析显示,实验/动物研究设计和作者数量与数量显著相关(IRR = 2.12, P = 0.011;IRR = 1.03, P = 0.002)和作者自引用百分比(IRR = 2.95, P = 0.003;Irr = 1.03, p = 0.012)。Scopus和《European Urology》的被引次数仅与作者自引次数显著相关。结论:泌尿外科非时性作者自引率高于普通医学文献,但与其他外科亚专科相似。这可能取决于研究设计和论文作者的数量。为了进行更全面的评价,未来的研究应该着眼于自我引用的背景。
{"title":"Author self-citations in the urology literature.","authors":"Vaibhav Aggarwal","doi":"10.1080/2090598X.2022.2056976","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2056976","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to determine the diachronous self-citation rate and the various article characteristics which can influence the rate and percentage of diachronous author self-citations using papers published in high-rank urology journals.</p><p><strong>Methods: </strong>We included all papers (N = 327 articles) published between January 2015 to April 2015 in the European Urology, The Journal of Urology and the BJU International. We determined author self-citations using the Scopus database and used negative binomial regression to determine which article characteristics affect self-citations.</p><p><strong>Results: </strong>262 articles (80.2%) contained at least one self-citation.The mean number and percentage of author self-citations were 6.5 and 14.2 respectively. Adjusted analysis showed that the experimental/animal study design and the number of authors were significantly associated with both the number (IRR = 2.12, P = 0.011; IRR = 1.03, P = 0.002) and percentage of author self-citations (IRR = 2.95, P = 0.003; IRR = 1.03, P = 0.012). The number of citations in the Scopus and publication in European Urology were significantly associated with only the number of author self-citations.</p><p><strong>Conclusion: </strong>Diachronous author self-citation rate in urology is higher compared to general medical literature but similar to other surgical subspecialties. It may depend on the study design and the number of authors in the paper. For a more comprehensive evaluation, future studies should look at the context in which self-citations were made.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 3","pages":"168-173"},"PeriodicalIF":1.5,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis 放疗与根治性前列腺切除术作为高危局部前列腺癌患者一线决定性治疗的比较:最新的系统综述和荟萃分析
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-03-30 DOI: 10.1080/2090598X.2022.2026010
A. Aydh, R. Motlagh, M. Abufaraj, K. Mori, S. Katayama, N. Grossmann, Pawel Rajawa, H. Mostafai, E. Laukhtina, B. Pradère, F. Quhal, V. Schuettfort, A. Briganti, P. Karakiewicz, Haron Fajkovic, S. Shariat
ABSTRACT Objective To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa). Methods We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS). Results A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16–1.65; and HR 1.55, 95% CI 1.25–1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76–1.34) and CSS (HR 0.69, 95% CI 0.45–1.06) between EBRT plus BT compared to RP. Conclusion While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa. Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy
【摘要】目的更新现有文献,比较外束放射治疗(EBRT)加或不加近距离放疗(BT)与根治性前列腺切除术(RP)对高危局限性前列腺癌(PCa)患者的治疗效果。方法我们对文献进行了系统回顾和荟萃分析,以评估高风险PCa患者接受EBRT合并或不合并BT与RP作为一线治疗的生存结果。我们在2021年1月查询了PubMed和Web of Science数据库。此外,在I2统计量存在或不存在异质性时,我们分别使用随机或固定效应元分析模型。我们对总生存期(OS)和癌症特异性生存期(CSS)进行了六项荟萃分析。结果共纳入27项研究,其中23项研究同时符合OS和CSS标准。与RP相比,单独EBRT的OS和CSS明显更差(风险比[HR] 1.38, 95%可信区间[CI] 1.16-1.65;HR 1.55, 95% CI 1.25-1.93)。然而,与RP相比,EBRT + BT在OS (HR 1.1, 95% CI 0.76-1.34)和CSS (HR 0.69, 95% CI 0.45-1.06)方面没有差异。结论在高危PCa患者中,单纯EBRT对肿瘤的控制效果似乎不如RP,但BT加药EBRT与RP效果无明显差异。这些数据支持除了EBRT外,还需要BT作为高风险PCa多模式RT的一部分。ADT:雄激素剥夺疗法;英国电信:近距离放射疗法;CSS:癌症特异性生存;HR:风险比;MFS:无转移生存期;MOOSE:流行病学观察性研究的meta分析;OR:优势比;OS:总生存期;PCa:前列腺癌;RR:相对风险;RP:根治性前列腺切除术;RCT:随机对照试验;(EB)RT:(外束)放射治疗
{"title":"Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis","authors":"A. Aydh, R. Motlagh, M. Abufaraj, K. Mori, S. Katayama, N. Grossmann, Pawel Rajawa, H. Mostafai, E. Laukhtina, B. Pradère, F. Quhal, V. Schuettfort, A. Briganti, P. Karakiewicz, Haron Fajkovic, S. Shariat","doi":"10.1080/2090598X.2022.2026010","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2026010","url":null,"abstract":"ABSTRACT Objective To present an update of the available literature on external beam radiation therapy (EBRT) with or without brachytherapy (BT) compared to radical prostatectomy (RP) for patients with high-risk localised prostate cancer (PCa). Methods We conducted a systematic review and meta-analysis of the literature assessing the survival outcomes in patients with high-risk PCa who received EBRT with or without BT compared to RP as the first-line therapy with curative intent. We queried PubMed and Web of Science database in January 2021. Moreover, we used random or fixed-effects meta-analytical models in the presence or absence of heterogeneity per the I2 statistic, respectively. We performed six meta-analyses for overall survival (OS) and cancer-specific survival (CSS). Results A total of 27 studies were selected with 23 studies being eligible for both OS and CSS. EBRT alone had a significantly worse OS and CSS compared to RP (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.16–1.65; and HR 1.55, 95% CI 1.25–1.93). However, there was no difference in OS (HR 1.1, 95% CI 0.76–1.34) and CSS (HR 0.69, 95% CI 0.45–1.06) between EBRT plus BT compared to RP. Conclusion While cancer control affected by EBRT alone seems inferior to RP in patients with high-risk PCa, BT additive to EBRT was not different from RP. These data support the need for BT in addition to EBRT as part of multimodal RT for high-risk PCa. Abbreviations: ADT: androgen-deprivation therapy; BT: brachytherapy; CSS: cancer-specific survival; HR: hazard ratio; MFS, metastatic-free survival; MOOSE: Meta-analyses of Observational Studies in Epidemiology; OR: odds ratio; OS: overall survival; PCa: prostate cancer; RR: relative risk; RP: radical prostatectomy; RCT: randomised controlled trials; (EB)RT: (external beam) radiation therapy","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"71 - 80"},"PeriodicalIF":1.5,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60071462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis 使用扩展前列腺癌症指数综合调查进行积极监测的癌症前列腺患者的健康相关生活质量:系统回顾和荟萃分析
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-02-27 DOI: 10.1080/2090598X.2021.2024368
Ahmed Abdelhafez, Khaled Hosny, A. El-Nahas, M. Liew
ABSTRACT Objective To examine the health-related quality of life (HRQoL) of patients with prostate cancer managed with active surveillance (AS) compared with those who receive definitive treatment using the Expanded Prostate Cancer Index Composite (EPIC) Survey. Methods We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and searched PubMed and ScienceDirect for articles published between April 2010 and April 2020. Eligible studies reported original data on the HRQoL of men undergoing AS for prostate cancer, including studies comparing AS to curative methods particularly radical prostatectomy, radiotherapy, and brachytherapy. Results We identified nine eligible articles, all were non-experimental observational studies of which seven were longitudinal and two were cross-sectional studies. The EPIC questionnaire was the main instrument used in all studies to assess the HRQoL. AS was noted to show the highest calculated mean score among management groups in all comparative studies at study endpoints including cross-sectional studies (95% confidence interval 2.17–5.75, P < 0.001). The maximum score deterioration for patients who were managed with AS in all studies was only 7.5 points (12.2%) after 2 years follow-up. AS had the least mean score decline among all management groups. Patients with a normal testosterone level were found to have high HRQoL scores. The number of prostate biopsies did not correlate with the HRQoL score. Conclusion Patients with prostate cancer managed with AS report less impacts on their HRQoL compared to patients who receive definitive treatments. However, further high-quality research with long-term data are required to help both the patient and the physician in making a well-informed management decision.
目的比较采用主动监测(AS)的前列腺癌患者与接受明确治疗的前列腺癌患者的健康相关生活质量(HRQoL),采用扩展前列腺癌指数综合调查(EPIC)。方法采用系统评价和荟萃分析首选报告项目(PRISMA)指南,检索PubMed和ScienceDirect 2010年4月至2020年4月间发表的文章。符合条件的研究报告了接受AS治疗前列腺癌男性HRQoL的原始数据,包括将AS与治疗方法,特别是根治性前列腺切除术、放疗和近距离放疗进行比较的研究。结果我们确定了9篇符合条件的文章,均为非实验观察性研究,其中7篇为纵向研究,2篇为横断面研究。EPIC问卷是所有研究中评估HRQoL的主要工具。值得注意的是,在包括横断面研究在内的所有比较研究终点,AS显示管理组的计算平均得分最高(95%置信区间2.17-5.75,P < 0.001)。在所有研究中,接受AS治疗的患者在2年随访后的最大评分下降仅为7.5分(12.2%)。在所有管理组中,AS组的平均得分下降幅度最小。睾酮水平正常的患者HRQoL评分较高。前列腺活检次数与HRQoL评分无相关性。结论:与接受明确治疗的患者相比,接受AS治疗的前列腺癌患者的HRQoL受到的影响较小。然而,需要进一步高质量的长期数据研究,以帮助患者和医生做出明智的管理决策。
{"title":"The health-related quality of life in patients with prostate cancer managed with active surveillance using the Expanded Prostate Cancer Index Composite survey: Systematic review and meta-analysis","authors":"Ahmed Abdelhafez, Khaled Hosny, A. El-Nahas, M. Liew","doi":"10.1080/2090598X.2021.2024368","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2024368","url":null,"abstract":"ABSTRACT Objective To examine the health-related quality of life (HRQoL) of patients with prostate cancer managed with active surveillance (AS) compared with those who receive definitive treatment using the Expanded Prostate Cancer Index Composite (EPIC) Survey. Methods We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and searched PubMed and ScienceDirect for articles published between April 2010 and April 2020. Eligible studies reported original data on the HRQoL of men undergoing AS for prostate cancer, including studies comparing AS to curative methods particularly radical prostatectomy, radiotherapy, and brachytherapy. Results We identified nine eligible articles, all were non-experimental observational studies of which seven were longitudinal and two were cross-sectional studies. The EPIC questionnaire was the main instrument used in all studies to assess the HRQoL. AS was noted to show the highest calculated mean score among management groups in all comparative studies at study endpoints including cross-sectional studies (95% confidence interval 2.17–5.75, P < 0.001). The maximum score deterioration for patients who were managed with AS in all studies was only 7.5 points (12.2%) after 2 years follow-up. AS had the least mean score decline among all management groups. Patients with a normal testosterone level were found to have high HRQoL scores. The number of prostate biopsies did not correlate with the HRQoL score. Conclusion Patients with prostate cancer managed with AS report less impacts on their HRQoL compared to patients who receive definitive treatments. However, further high-quality research with long-term data are required to help both the patient and the physician in making a well-informed management decision.","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"61 - 70"},"PeriodicalIF":1.5,"publicationDate":"2022-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42679481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of a tadalafil 5-mg single daily dose on lifelong premature ejaculation: A single-blinded placebo-controlled study 他达拉非5mg单日剂量对终身早泄的影响:一项单盲安慰剂对照研究
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-02-26 DOI: 10.1080/2090598X.2021.2007464
A. H. Abou Faddan, H. Gaber, Daniar Oamonov
ABSTRACT Objective To investigate the effectiveness and safety of a tadalafil 5-mg single daily dose in the treatment of lifelong premature ejaculation (PE). Patients and Methods A total of 55 men with lifelong PE were enrolled in this study. The intravaginal ejaculatory latency time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) were used to assess the efficacy of tadalafil. Baseline recording of the IELT (using a stopwatch) and PEDT was done. Patients were randomised to take a single daily dose of tadalafil 5 mg or placebo. Re-assessment was done by IELT and PEDT after 1 and 3 months. Results As regard, age, number of children, frequency of intercourse and duration of PE there are no statically significant differences between both groups. In both the tadalafil 5-mg and placebo groups the IELT statically significantly increased after 1 month by a mean (SD) of 4.8 (4.7) and 5 (4.9) s, and after 3 months by a mean (SD) of 6.6 (7) and 4.5 (9) s; and the PEDT scores significantly improved after 1 month by a mean (SD) of 2.1 (1.9) and 2 (1.5), and after 3 months by a mean (SD) of 3.5 (2.5) and 3.3 (2.2). However, there is was no statically significant difference between the tadalafil 5-mg and placebo groups for the IELT and PEDT at baseline or after 1 and 3 months of treatment. Conclusions Despite 5-mg tadalafil once daily being safe and it showed only a slight improvement in IELT and PEDT in the treatment of lifelong PE, failing to show any statistically significant difference from the placebo drug. Abbreviations: ED: erectile dysfunction; 5-HT: 5-hydroxytryptamine (serotonin); IELT: the intravaginal ejaculation latency time; ISSM: International Society of Sexual Medicine; PE: premature ejaculation; PEDT: Premature Ejaculation Diagnostic Tool; PDE5i: phosphodiesterase-5 inhibitor; SSRI: selective serotonin reuptake inhibitor
目的探讨他达拉非5 mg每日单剂量治疗终身早泄(PE)的有效性和安全性。患者和方法本研究共纳入55例终身PE患者。采用阴道内射精潜伏期(IELT)和早泄诊断工具(PEDT)评估他达拉非的疗效。完成了雅思(使用秒表)和PEDT的基线记录。患者被随机分为两组,每日服用5毫克的他达拉非或安慰剂。分别于1个月和3个月后进行雅思和PEDT再评估。结果两组患者在年龄、子女数、性交次数、运动时间等方面差异无统计学意义。在他达拉非5-mg组和安慰剂组中,雅思成绩在1个月后平均(SD)增加4.8(4.7)和5(4.9)秒,在3个月后平均(SD)增加6.6(7)和4.5(9)秒;1个月后PEDT评分平均(SD)为2.1(1.9)和2(1.5),3个月后平均(SD)为3.5(2.5)和3.3(2.2)。然而,在基线或治疗1个月和3个月后,他达拉非5mg组和安慰剂组在雅思和PEDT方面没有统计学上的显著差异。结论:尽管每日一次5mg他达拉非是安全的,并且在终身PE的治疗中,他达拉非仅对雅思和PEDT有轻微的改善,但与安慰剂药物相比没有统计学上的显著差异。缩写:ED:勃起功能障碍;5-HT: 5-羟色胺(血清素);雅思:阴道内射精潜伏期;国际性医学学会;PE:早泄;早泄诊断工具;PDE5i:磷酸二酯酶-5抑制剂;选择性血清素再摄取抑制剂
{"title":"Effect of a tadalafil 5-mg single daily dose on lifelong premature ejaculation: A single-blinded placebo-controlled study","authors":"A. H. Abou Faddan, H. Gaber, Daniar Oamonov","doi":"10.1080/2090598X.2021.2007464","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2007464","url":null,"abstract":"ABSTRACT Objective To investigate the effectiveness and safety of a tadalafil 5-mg single daily dose in the treatment of lifelong premature ejaculation (PE). Patients and Methods A total of 55 men with lifelong PE were enrolled in this study. The intravaginal ejaculatory latency time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) were used to assess the efficacy of tadalafil. Baseline recording of the IELT (using a stopwatch) and PEDT was done. Patients were randomised to take a single daily dose of tadalafil 5 mg or placebo. Re-assessment was done by IELT and PEDT after 1 and 3 months. Results As regard, age, number of children, frequency of intercourse and duration of PE there are no statically significant differences between both groups. In both the tadalafil 5-mg and placebo groups the IELT statically significantly increased after 1 month by a mean (SD) of 4.8 (4.7) and 5 (4.9) s, and after 3 months by a mean (SD) of 6.6 (7) and 4.5 (9) s; and the PEDT scores significantly improved after 1 month by a mean (SD) of 2.1 (1.9) and 2 (1.5), and after 3 months by a mean (SD) of 3.5 (2.5) and 3.3 (2.2). However, there is was no statically significant difference between the tadalafil 5-mg and placebo groups for the IELT and PEDT at baseline or after 1 and 3 months of treatment. Conclusions Despite 5-mg tadalafil once daily being safe and it showed only a slight improvement in IELT and PEDT in the treatment of lifelong PE, failing to show any statistically significant difference from the placebo drug. Abbreviations: ED: erectile dysfunction; 5-HT: 5-hydroxytryptamine (serotonin); IELT: the intravaginal ejaculation latency time; ISSM: International Society of Sexual Medicine; PE: premature ejaculation; PEDT: Premature Ejaculation Diagnostic Tool; PDE5i: phosphodiesterase-5 inhibitor; SSRI: selective serotonin reuptake inhibitor","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"100 - 104"},"PeriodicalIF":1.5,"publicationDate":"2022-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44589609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffusion of robot-assisted radical cystectomy: Nationwide trends, predictors, and association with continent urinary diversion. 机器人辅助根治性膀胱切除术的扩散:全国趋势、预测因素以及与大陆性尿路改道的关联。
IF 1.3 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-02-16 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2032562
Ahmed Elshabrawy, Hanzhang Wang, Furkan Dursun, Dharam Kaushik, Michael Liss, Robert S Svatek, Ahmed M Mansour

Objectives: To assess the utilisation trends of robot-assisted radical cystectomy (RARC), rates of performing continent urinary diversions (CUDs), and impact of diffusion of RARC on CUD rates.

Methods: We investigated the National Cancer Database for patients with muscle-invasive bladder cancer (MIBC) who underwent RC between 2004 and 2015. Patients were stratified by surgical technique into open (ORC) and RARC groups, and by type of urinary diversion into continent (CUD) and ileal conduit (ICUD) groups. Linear regression models were fitted to evaluate time trends for surgery and conversion techniques. Multivariate logistic regression models were utilised to identify independent predictors of RARC and CUD.

Results: A total of 14466 patients underwent RC for MIBC, of which 4914 (34%) underwent RARC. There was a significant increase in adoption of RARC from 22% in 2010 to 40% in 2015 (R2 = 0.96, P < 0.001), this was not associated with a change in the rates of CUD over the same period (P = 0.22). Across all years, ICUD was the primary type of urinary diversion, CUD was only offered in 12% in 2010 compared to 9.9% in 2015 (R2 = 0.33, P = 0.22). Multivariate analysis identified male gender (odds ratio [OR] 1.18, P = 0.03), academic centres (OR 1.74, P = 0.001), and lower T stage (T4 vs T2; OR 0.78, P = 0.03) as independent predictors of CUD, while surgical technique was not associated with odds of receiving CUD (P = 0.8).

Conclusions: There is significant nationwide increasing trend of adoption of RARC. This diffusion was not associated with a decline in CUD, which remains significantly underutilised in both ORC and RARC groups. Abbreviations CUD: continent urinary diversion; ICD-O: International Classification of Diseases for Oncology; ICUD: ileal conduit urinary diversion; (N)MIBC: (non-)muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; NCDB: National Cancer Database; OR: odds ratio;(O)(RA)RC: (open) (robot-assisted) radical cystectomy.

目的:评估机器人辅助根治性膀胱切除术(RARC)的使用趋势、实施持续性尿路转流术(CUD)的比率以及 RARC 的普及对 CUD 比率的影响:我们在全国癌症数据库中调查了2004年至2015年间接受RARC手术的肌层浸润性膀胱癌(MIBC)患者。根据手术技术将患者分为开放(ORC)组和 RARC 组,根据尿路转流类型将患者分为大陆(CUD)组和回肠导管(ICUD)组。线性回归模型用于评估手术和转换技术的时间趋势。利用多变量逻辑回归模型确定 RARC 和 CUD 的独立预测因素:共有 14466 名 MIBC 患者接受了 RC,其中 4914 人(34%)接受了 RARC。RARC的采用率从2010年的22%大幅增至2015年的40%(R2 = 0.96,P P = 0.22)。在所有年份中,ICUD是主要的尿路改道类型,2010年只有12%的患者接受了CUD,而2015年为9.9%(R2 = 0.33,P = 0.22)。多变量分析发现,男性性别(几率比 [OR] 1.18,P = 0.03)、学术中心(OR 1.74,P = 0.001)和较低的 T 期(T4 vs T2;OR 0.78,P = 0.03)是 CUD 的独立预测因素,而手术技术与接受 CUD 的几率无关(P = 0.8):结论:在全国范围内,RARC的采用呈明显增长趋势。结论:在全国范围内,RARC 的采用呈显著上升趋势,但这与 CUD 的减少无关,在 ORC 和 RARC 组中,CUD 的使用率仍明显偏低。缩写 CUD:大陆性尿路改道术;ICD-O:国际肿瘤疾病分类;ICUD:回肠导尿管尿路改道术;(N)MIBC:(非)肌肉浸润性膀胱癌;NAC:新辅助化疗;NCDB:国家癌症数据库;OR:几率比;(O)(RA)RC:(开放)(机器人辅助)根治性膀胱切除术。
{"title":"Diffusion of robot-assisted radical cystectomy: Nationwide trends, predictors, and association with continent urinary diversion.","authors":"Ahmed Elshabrawy, Hanzhang Wang, Furkan Dursun, Dharam Kaushik, Michael Liss, Robert S Svatek, Ahmed M Mansour","doi":"10.1080/2090598X.2022.2032562","DOIUrl":"10.1080/2090598X.2022.2032562","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the utilisation trends of robot-assisted radical cystectomy (RARC), rates of performing continent urinary diversions (CUDs), and impact of diffusion of RARC on CUD rates.</p><p><strong>Methods: </strong>We investigated the National Cancer Database for patients with muscle-invasive bladder cancer (MIBC) who underwent RC between 2004 and 2015. Patients were stratified by surgical technique into open (ORC) and RARC groups, and by type of urinary diversion into continent (CUD) and ileal conduit (ICUD) groups. Linear regression models were fitted to evaluate time trends for surgery and conversion techniques. Multivariate logistic regression models were utilised to identify independent predictors of RARC and CUD.</p><p><strong>Results: </strong>A total of 14466 patients underwent RC for MIBC, of which 4914 (34%) underwent RARC. There was a significant increase in adoption of RARC from 22% in 2010 to 40% in 2015 (R<sup>2</sup> = 0.96, <i>P</i> < 0.001), this was not associated with a change in the rates of CUD over the same period (<i>P</i> = 0.22). Across all years, ICUD was the primary type of urinary diversion, CUD was only offered in 12% in 2010 compared to 9.9% in 2015 (R<sup>2</sup> = 0.33, <i>P</i> = 0.22). Multivariate analysis identified male gender (odds ratio [OR] 1.18, <i>P</i> = 0.03), academic centres (OR 1.74, <i>P</i> = 0.001), and lower T stage (T4 vs T2; OR 0.78, <i>P</i> = 0.03) as independent predictors of CUD, while surgical technique was not associated with odds of receiving CUD (<i>P</i> = 0.8).</p><p><strong>Conclusions: </strong>There is significant nationwide increasing trend of adoption of RARC. This diffusion was not associated with a decline in CUD, which remains significantly underutilised in both ORC and RARC groups. <b>Abbreviations</b> CUD: continent urinary diversion; ICD-O: International Classification of Diseases for Oncology; ICUD: ileal conduit urinary diversion; (N)MIBC: (non-)muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; NCDB: National Cancer Database; OR: odds ratio;(O)(RA)RC: (open) (robot-assisted) radical cystectomy.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 3","pages":"159-167"},"PeriodicalIF":1.3,"publicationDate":"2022-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repeated microdissection testicular sperm extraction in patients with non-obstructive azoospermia: Outcome and predictive factors. 非阻塞性无精子症患者反复显微解剖睾丸精子提取:结果和预测因素。
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-01-24 eCollection Date: 2022-01-01 DOI: 10.1080/2090598X.2022.2028066
Ibrahim Fathi Ghalayini, Rami Alazab, Omar Halalsheh, Alia H Al-Mohtaseb, Mohammed A Al-Ghazo

Objective: To assess the feasibility of repeated sperm recovery in patients with non-obstructive azoospermia (NOA), as little is known about the extraction rate in repeated microdissection testicular sperm extraction (microTESE) in these patients.

Patients and methods: A total of 134 men with NOA had their first sperm recovery between January 2013 and February 2020. Repeated microTESE had been done mostly for patients with a successful initial retrieval.

Results: In the 323 procedures performed on the 134 men with NOA, sperm could be retrieved in 236 procedures (73.1%). A total of 88, 61 and 40 men underwent two, three and four sperm retrievals, respectively. In these cycles, sperm could be extracted in 65 (73.9%), 53 (86.9%) and 37 (92.5%) men, respectively. During the first microTESE procedure, sperm could be extracted in 81 (60.4%) men with NOA. In all, the success rate was significantly different between subgroups, showing highest rate in hypospermatogenesis cases (95.6%), followed by maturation arrest (58.5%), and Sertoli cell-only syndrome (56.0%). However, this difference was not significant at the third and fourth repeated microTESE. The FSH levels and testicular volume were among the noticeable factors affecting success of sperm retrieval. The duration between the first and second biopsies significantly increased the success rate by a factor of 1.3-fold/month; however, afterwards, the duration did not play any role in the success of microTESE. The success of previous trial significantly increased the probability of success by 10.1-fold in the second trial, 5.6-fold in the third trial, and 16.5 folds in the fourth.

Conclusion: Repeated MD -TESE ensures a high sperm recovery rate in patients with NOA. These data also show that when no spermatozoa can be obtained after thawing cryopreserved testicular sperm for ICSI in NOA patients, a repeat microTESE procedure can be planned.

Abbreviations: ICSI: intracytoplasmic sperm injection; IVF: in vitro fertilisation; MA: maturation arrest; (N)OA: (non-)obstructive azoospermia; OR: odds ratio; SCOS, Sertoli cell-only syndrome; SRR: spermatozoa retrieval rate; (micro)TESE: (microdissection) testicular sperm extraction.

目的:探讨非阻塞性无精子症(NOA)患者反复显微解剖睾丸精子提取术(microTESE)的成功率,探讨反复精子恢复的可行性。患者和方法:在2013年1月至2020年2月期间,共有134名NOA男性进行了第一次精子恢复。重复microTESE主要用于首次成功取出的患者。结果:在134例NOA患者的323例手术中,236例(73.1%)可获得精子。共有88名、61名和40名男性分别接受了2次、3次和4次精子提取。在这些周期中,分别有65名(73.9%)、53名(86.9%)和37名(92.5%)男性可以提取精子。在第一次microTESE手术中,81名(60.4%)NOA男性可以提取精子。总而言之,亚组间的成功率有显著差异,低精子发生的成功率最高(95.6%),其次是成熟阻滞(58.5%)和仅支持细胞综合征(56.0%)。然而,在第三次和第四次重复的microTESE中,这种差异并不显著。FSH水平和睾丸体积是影响精子提取成功的显著因素。第一次和第二次活检之间的时间间隔显著提高了成功率1.3倍/月;然而,此后,持续时间对microTESE的成功没有任何作用。前一次试验的成功使第二次试验的成功概率显著提高10.1倍,第三次试验提高5.6倍,第四次试验提高16.5倍。结论:重复的MD -TESE是NOA患者精子恢复率高的保证。这些数据还表明,当NOA患者冷冻保存的睾丸精子解冻后无法获得用于ICSI的精子时,可以计划重复microTESE手术。ICSI:胞浆内单精子注射;IVF:体外受精;MA:成熟阻滞;OA:(非)阻塞性无精子症;OR:优势比;SCOS,单纯支持细胞综合征;SRR:精子回收率;(显微解剖)睾丸精子提取。
{"title":"Repeated microdissection testicular sperm extraction in patients with non-obstructive azoospermia: Outcome and predictive factors.","authors":"Ibrahim Fathi Ghalayini,&nbsp;Rami Alazab,&nbsp;Omar Halalsheh,&nbsp;Alia H Al-Mohtaseb,&nbsp;Mohammed A Al-Ghazo","doi":"10.1080/2090598X.2022.2028066","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2028066","url":null,"abstract":"<p><strong>Objective: </strong>To assess the feasibility of repeated sperm recovery in patients with non-obstructive azoospermia (NOA), as little is known about the extraction rate in repeated microdissection testicular sperm extraction (microTESE) in these patients.</p><p><strong>Patients and methods: </strong>A total of 134 men with NOA had their first sperm recovery between January 2013 and February 2020. Repeated microTESE had been done mostly for patients with a successful initial retrieval.</p><p><strong>Results: </strong>In the 323 procedures performed on the 134 men with NOA, sperm could be retrieved in 236 procedures (73.1%). A total of 88, 61 and 40 men underwent two, three and four sperm retrievals, respectively. In these cycles, sperm could be extracted in 65 (73.9%), 53 (86.9%) and 37 (92.5%) men, respectively. During the first microTESE procedure, sperm could be extracted in 81 (60.4%) men with NOA. In all, the success rate was significantly different between subgroups, showing highest rate in hypospermatogenesis cases (95.6%), followed by maturation arrest (58.5%), and Sertoli cell-only syndrome (56.0%). However, this difference was not significant at the third and fourth repeated microTESE. The FSH levels and testicular volume were among the noticeable factors affecting success of sperm retrieval. The duration between the first and second biopsies significantly increased the success rate by a factor of 1.3-fold/month; however, afterwards, the duration did not play any role in the success of microTESE. The success of previous trial significantly increased the probability of success by 10.1-fold in the second trial, 5.6-fold in the third trial, and 16.5 folds in the fourth.</p><p><strong>Conclusion: </strong>Repeated MD -TESE ensures a high sperm recovery rate in patients with NOA. These data also show that when no spermatozoa can be obtained after thawing cryopreserved testicular sperm for ICSI in NOA patients, a repeat microTESE procedure can be planned.</p><p><strong>Abbreviations: </strong>ICSI: intracytoplasmic sperm injection; IVF: in vitro fertilisation; MA: maturation arrest; (N)OA: (non-)obstructive azoospermia; OR: odds ratio; SCOS, Sertoli cell-only syndrome; SRR: spermatozoa retrieval rate; (micro)TESE: (microdissection) testicular sperm extraction.</p>","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 3","pages":"137-143"},"PeriodicalIF":1.5,"publicationDate":"2022-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40588980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Can tranexamic acid in irrigation fluid reduce blood loss during monopolar transurethral resection of the prostate? A randomised controlled trial 冲洗液中的氨甲环酸能减少经尿道前列腺单极切除时的失血量吗?一项随机对照试验
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-01-23 DOI: 10.1080/2090598X.2022.2026011
A. Tawfick, Waleed Mousa, Ahmed Fawaz El-Zhary, Ahmed Saafan
ABSTRACT Objective To assess the efficacity and safety of using tranexamic acid (TXA) in the irrigation solution during transurethral resection of the prostate (TURP). Patients and Methods A total of 50 patients undergoing TURP for benign prostatic hyperplasia were prospectively randomised in a controlled clinical trial and distributed into two groups. Group A received 0.1% TXA 1000 mg (10 mL) in 1 L of irrigation solution of sterile wash (glycine) during surgery, while Group B received 10 mL distilled water (placebo) in 1 L of irrigation solution of sterile wash (glycine) during surgery. At the end of surgery, a three-way catheter was inserted in the bladder. Group A received local 500 mg of TXA (5 mL), which was dissolved in 100 mL of normal saline solution, while Group B received distilled water (5 mL) dissolved in 100 mL of normal saline solution after which the catheter was clamped. The serum haemoglobin (Hb) concentration, haematocrit (HCT), blood loss volume, Hb concentration in the irrigation fluid, and bladder irrigation volumes were compared between the two groups at three time-points: preoperatively and at 4- and 24-h postoperatively. Coagulation function, complications, thromboembolic events, quality of endoscopic view, surgery duration, and hospital stay were also noted. Results Group A had significantly lower blood loss intraoperatively, and at 4- and 24-h postoperatively compared to the control group (P < 0.05). The serum Hb concentration, HCT, Hb concentration in the irrigation fluid, and bladder irrigation volumes were significantly lower in the TXA group vs the control group (P < 0.001). The shortening of the surgery duration and improvement in the quality of the endoscopic view were significantly noted in the TXA group (P = 0.001). However, no thromboembolic events occurred in either group. Conclusion The use of TXA in the irrigation fluid during TURP and injection into the bladder postoperatively can reduce blood loss and the need for blood transfusion without increasing the risk of thrombosis.
目的评价经尿道前列腺电切术(TURP)冲洗液中使用氨甲环酸(TXA)的有效性和安全性。患者和方法将50例接受前列腺增生手术的患者随机分为两组。A组术中给予0.1% TXA 1000 mg (10 mL),加入1 L无菌洗涤(甘氨酸)冲洗液;B组术中给予蒸馏水10 mL(安慰剂),加入1 L无菌洗涤(甘氨酸)冲洗液。手术结束时,在膀胱中插入三路导尿管。A组局部给予TXA 500 mg (5 mL),溶解于100 mL生理盐水溶液中;B组给予蒸馏水5 mL,溶解于100 mL生理盐水溶液中,夹住导管。比较两组患者术前、术后4小时和24小时三个时间点的血清血红蛋白(Hb)浓度、红细胞压积(HCT)、出血量、灌洗液中Hb浓度和膀胱灌洗液体积。凝血功能、并发症、血栓栓塞事件、内镜观察质量、手术时间和住院时间也被记录下来。结果A组术中、术后4 h、24 h出血量均显著低于对照组(P < 0.05)。TXA组血清Hb浓度、HCT、灌洗液Hb浓度、膀胱灌洗液容积均显著低于对照组(P < 0.001)。TXA组手术时间缩短,内镜影像质量改善显著(P = 0.001)。然而,两组均未发生血栓栓塞事件。结论在TURP术中使用灌洗液中加入TXA,术后膀胱内注射TXA可减少出血量和输血需求,且不增加血栓形成的风险。
{"title":"Can tranexamic acid in irrigation fluid reduce blood loss during monopolar transurethral resection of the prostate? A randomised controlled trial","authors":"A. Tawfick, Waleed Mousa, Ahmed Fawaz El-Zhary, Ahmed Saafan","doi":"10.1080/2090598X.2022.2026011","DOIUrl":"https://doi.org/10.1080/2090598X.2022.2026011","url":null,"abstract":"ABSTRACT Objective To assess the efficacity and safety of using tranexamic acid (TXA) in the irrigation solution during transurethral resection of the prostate (TURP). Patients and Methods A total of 50 patients undergoing TURP for benign prostatic hyperplasia were prospectively randomised in a controlled clinical trial and distributed into two groups. Group A received 0.1% TXA 1000 mg (10 mL) in 1 L of irrigation solution of sterile wash (glycine) during surgery, while Group B received 10 mL distilled water (placebo) in 1 L of irrigation solution of sterile wash (glycine) during surgery. At the end of surgery, a three-way catheter was inserted in the bladder. Group A received local 500 mg of TXA (5 mL), which was dissolved in 100 mL of normal saline solution, while Group B received distilled water (5 mL) dissolved in 100 mL of normal saline solution after which the catheter was clamped. The serum haemoglobin (Hb) concentration, haematocrit (HCT), blood loss volume, Hb concentration in the irrigation fluid, and bladder irrigation volumes were compared between the two groups at three time-points: preoperatively and at 4- and 24-h postoperatively. Coagulation function, complications, thromboembolic events, quality of endoscopic view, surgery duration, and hospital stay were also noted. Results Group A had significantly lower blood loss intraoperatively, and at 4- and 24-h postoperatively compared to the control group (P < 0.05). The serum Hb concentration, HCT, Hb concentration in the irrigation fluid, and bladder irrigation volumes were significantly lower in the TXA group vs the control group (P < 0.001). The shortening of the surgery duration and improvement in the quality of the endoscopic view were significantly noted in the TXA group (P = 0.001). However, no thromboembolic events occurred in either group. Conclusion The use of TXA in the irrigation fluid during TURP and injection into the bladder postoperatively can reduce blood loss and the need for blood transfusion without increasing the risk of thrombosis.","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"94 - 99"},"PeriodicalIF":1.5,"publicationDate":"2022-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46172925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prostate cancer in the Arab world: Bibliometric review and research priority recommendations 阿拉伯世界的前列腺癌症:文献计量学综述和研究优先建议
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-01-23 DOI: 10.1080/2090598X.2021.2024984
A. H. Ali, H. Awada, H. Nassereldine, M. Zeineddine, Zahy Abdul Sater, A. El-Hajj, D. Mukherji
ABSTRACT Objective To conduct a scoping review examining the status of prostate cancer research in Arab countries and systematically map publications across the cancer care pathway. Prostate cancer incidence has been rising in the Arab world and tackling its increasing burden will require evidence-based policies. Methods We searched Medline, PubMed and Scopus for peer-reviewed publications related to both our research topic and countries of interest by using controlled vocabulary and keywords. Search results were limited for the period between 2000 and 2020, screened for duplicates, and then included in our study based on pre-specified eligibility criteria. We used a structured data extraction form to extract information related to the article, its methodology, its cancer care pathway, funding status, and authorship. Results A total of 4142 publications were retrieved from our search, of which 874 articles remained after applying eligibility criteria. Trends show a steady increase in prostate cancer research in the Arab world. Most studies were focussed on diagnosis and treatment, whereas a lack in studies concerning screening and prevention, as well as epidemiological data, was evident. Most studies were not funded and had no female author. Country gross domestic product and population were positively correlated with its research output. The USA had the highest number of corresponding authors. The majority of Arab-based studies did not involve collaborations with other countries. Most research conducted was basic or clinical studies with a low level of evidence. Conclusion Our present review identified significant gaps and limitations in prostate cancer research in Arab countries. Priority areas for research investment have also been highlighted as a first step towards context-specific health policies. Abbreviations ASR: age-standardised rate; COVID-19: coronavirus disease 2019; GDP: gross domestic product; HDI: Human Development Index; KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates
摘要目的对阿拉伯国家癌症前列腺研究现状进行范围界定,并系统地绘制癌症治疗途径的出版物。阿拉伯世界前列腺癌症发病率一直在上升,解决其日益增加的负担需要循证政策。方法我们使用受控词汇和关键词在Medline、PubMed和Scopus上搜索与我们的研究主题和感兴趣国家相关的同行评审出版物。搜索结果在2000年至2020年期间受到限制,进行了重复筛选,然后根据预先指定的资格标准纳入我们的研究。我们使用结构化数据提取表来提取与文章、文章方法、癌症治疗途径、资金状况和作者相关的信息。结果我们共检索到4142篇出版物,其中874篇在应用资格标准后仍然存在。趋势显示,阿拉伯世界对前列腺癌症的研究稳步增加。大多数研究都集中在诊断和治疗上,而明显缺乏有关筛查和预防的研究以及流行病学数据。大多数研究没有得到资助,也没有女性作者。国家国内生产总值和人口与其研究产出呈正相关。美国的通讯作者数量最多。大多数基于阿拉伯的研究没有涉及与其他国家的合作。大多数研究都是基础或临床研究,证据水平较低。结论我们目前的综述确定了阿拉伯国家在前列腺癌症研究方面的重大差距和局限性。研究投资的优先领域也被强调为制定针对具体情况的卫生政策的第一步。缩写ASR:年龄标准化率;新冠肺炎:2019冠状病毒病;国内生产总值:国内生产总值;人类发展指数:人类发展指数;KSA:沙特阿拉伯王国;阿联酋:阿拉伯联合酋长国
{"title":"Prostate cancer in the Arab world: Bibliometric review and research priority recommendations","authors":"A. H. Ali, H. Awada, H. Nassereldine, M. Zeineddine, Zahy Abdul Sater, A. El-Hajj, D. Mukherji","doi":"10.1080/2090598X.2021.2024984","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2024984","url":null,"abstract":"ABSTRACT Objective To conduct a scoping review examining the status of prostate cancer research in Arab countries and systematically map publications across the cancer care pathway. Prostate cancer incidence has been rising in the Arab world and tackling its increasing burden will require evidence-based policies. Methods We searched Medline, PubMed and Scopus for peer-reviewed publications related to both our research topic and countries of interest by using controlled vocabulary and keywords. Search results were limited for the period between 2000 and 2020, screened for duplicates, and then included in our study based on pre-specified eligibility criteria. We used a structured data extraction form to extract information related to the article, its methodology, its cancer care pathway, funding status, and authorship. Results A total of 4142 publications were retrieved from our search, of which 874 articles remained after applying eligibility criteria. Trends show a steady increase in prostate cancer research in the Arab world. Most studies were focussed on diagnosis and treatment, whereas a lack in studies concerning screening and prevention, as well as epidemiological data, was evident. Most studies were not funded and had no female author. Country gross domestic product and population were positively correlated with its research output. The USA had the highest number of corresponding authors. The majority of Arab-based studies did not involve collaborations with other countries. Most research conducted was basic or clinical studies with a low level of evidence. Conclusion Our present review identified significant gaps and limitations in prostate cancer research in Arab countries. Priority areas for research investment have also been highlighted as a first step towards context-specific health policies. Abbreviations ASR: age-standardised rate; COVID-19: coronavirus disease 2019; GDP: gross domestic product; HDI: Human Development Index; KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"81 - 87"},"PeriodicalIF":1.5,"publicationDate":"2022-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47836939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme 五个中东国家成年人群中良性前列腺增生的患病率:SNAPSHOT计划的结果
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-01-02 DOI: 10.1080/2090598X.2021.2010451
A. Noweir, Ashraf J Abusamra, Abdelqader Al Zarooni, M. Binbay, A. Doble, L. Tariq, F. Aziz, A. El Hasnaoui
ABSTRACT Objectives To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster). Subjects and Methods The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L). Results In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3–15.4%) in Turkey, to 23.76% (95% CI 21.8–25.6%) in Egypt, and 23.79% (95% CI 21.2–26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%; P < 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (P < 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (P < 0.001). Conclusion The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.
摘要目的介绍五个中东国家(埃及、土耳其、科威特、沙特阿拉伯和阿拉伯联合酋长国;后三个国家形成海湾集群)的良性前列腺增生(BPH)患病率数据。受试者和方法SNAPSHOT计划是一项多国、横断面的流行病学调查,通过电话对成年普通人群进行随机抽样。根据过去12个月的诊断、症状和治疗,如果受试者符合筛查标准,则被认为患有前列腺增生。估计了目前的患病率(过去12个月)。通过多变量逻辑回归研究与合并症的相关性。使用三级EuroQol五维度问卷(EQ-5D-3L)评估生活质量(QoL)。结果在参加SNAPSHOT计划的33486名受试者中,5034人为年龄≥50岁的男性。总共有998名男性符合前列腺增生筛查标准。良性前列腺增生的总体患病率在土耳其为13.84%(95%置信区间[CI]12.3-15.4%),在埃及为23.76%(95%可信区间21.8-25.6%),在海湾地区为23.79%(95%可信范围21.2-26.3%)。与非BPH人群相比,患有BPH的男性合并症发生率更高(57%对31%;P<0.001)。与BPH相关的主要合并症是心血管、肾脏和糖尿病(P<0.001),与年龄≥50岁的男性普通人群(0.9)相比,EQ-5D-3L效用值(0.8)较低(P<0.001),这表明需要更好地了解疾病的管理,以减少对医疗保健系统的影响。
{"title":"Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme","authors":"A. Noweir, Ashraf J Abusamra, Abdelqader Al Zarooni, M. Binbay, A. Doble, L. Tariq, F. Aziz, A. El Hasnaoui","doi":"10.1080/2090598X.2021.2010451","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2010451","url":null,"abstract":"ABSTRACT Objectives To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster). Subjects and Methods The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L). Results In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3–15.4%) in Turkey, to 23.76% (95% CI 21.8–25.6%) in Egypt, and 23.79% (95% CI 21.2–26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%; P < 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (P < 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (P < 0.001). Conclusion The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"14 - 23"},"PeriodicalIF":1.5,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49550567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Short- and long-term follow-up results of daily 5-mg tadalafil as a treatment for erectile dysfunction and premature ejaculation 每日5mg他达拉非治疗勃起功能障碍和早泄的短期和长期随访结果
IF 1.5 Q3 UROLOGY & NEPHROLOGY Pub Date : 2022-01-02 DOI: 10.1080/2090598X.2021.2024695
Tarek Mohamed Gharib, I. Abdel-Al, A. Elatreisy, W. Kandeel, W. El-Shaer, Abdrabuh M. Abdrabuh, El- Sayed Mohamed Salih, A. Sebaey
ABSTRACT Objective To evaluate the safety and effectiveness of daily 5-mg tadalafil treatment for men who have erectile dysfunction (ED) and premature ejaculation (PE), and to assess the long-term follow-up for ED and PE improvement persistence years after the cessation of medication. Patients and Methods A prospective, single-blind, randomised study included 160 patients with ED and PE. All were evaluated using the International Index of Erectile Function (IIEF-5) questionnaire to evaluate ED and intravaginal ejaculatory latency time (IELT) for PE. Patients were subdivided into two equal groups. Group I (80 patients) treated with daily 5-mg tadalafil for 3 months, and Group II (80 patients) treated with a placebo for the same period. After 3 months of treatment and 2 years later after cessation of tadalafil, all patients were assessed for ED and PE. Results The mean (SD) IELT and IIEF-5 score pre-treatment were 37 (11.24) s and 13.2 (4.2) for Group I, while in Group II they were 35.98 (10.8) s and 13.12 (4.11), respectively. After 3 months of treatment, the mean (SD) IELT in Group I showed a highly significant improvement from 37 (11.24) s to 120.5 (47.37) s (P < 0.001) but Group II showed no significant improvement from baseline to [39.43 (13.6) s; P > 0.05]. For the IIEF-5 score, there was a highly significant improvement from baseline to 20.45 (4.5) in Group I (P < 0.001), while there was no significant difference in Group II from baseline to [15 (4.84); P > 0.05]. At 2 years after cessation of tadalafil, there was statistically significant improvement in the IELT and IIEF-5 from baseline to endpoint . Conclusion Oral daily 5-mg tadalafil was effective, tolerable, and safe treatment for patients with ED and PE. Long-term follow-up at 2 years confirmed the persistence of a significant improvement for both ED and PE. Abbreviations: ED: erectile dysfunction; IIEF-5: five-item version of the International Index of Erectile Function questionnaire; IELT: intravaginal ejaculatory latency time; OAD: once-daily; PDE5i: phosphodiesterase-5 inhibitors; PE: premature ejaculation; PRN: pro re nata
摘要目的评价每日5mg他达拉非治疗男性勃起功能障碍(ED)和早泄(PE)的安全性和有效性,并评估停药后ED和早泄改善持续数年的长期随访情况。患者和方法一项前瞻性、单盲、随机研究纳入160名ED和PE患者。所有患者均使用国际勃起功能指数(IIEF-5)问卷进行评估,以评估PE的ED和阴道内射精潜伏期(IELT)。患者被分为两组。第一组(80名患者)每天服用5mg他达拉非治疗3个月,第二组(80例患者)同期服用安慰剂。治疗3个月后和停药2年后,对所有患者进行ED和PE评估。结果I组治疗前IELT和IIEF-5评分的平均值(SD)分别为37(11.24)s和13.2(4.2),而II组分别为35.98(10.8)s和13.12(4.11)。治疗3个月后,I组的平均(SD)IELT从37(11.24)s显著改善到120.5(47.37)s(P<0.001),但II组从基线到[39.43(13.6)s没有显著改善;P>0.05]。对于IIEF-5评分,I组从基线至20.45(4.5)有非常显著的改善(P<001),而第II组从基线到[15(4.84);P>0.05]没有显著差异。在停用他达拉非2年后,从基线到终点,IELT和IIEF-5有统计学显著改善。结论每日口服5mg他达拉非对ED和PE患者是有效、耐受和安全的治疗方法。2年的长期随访证实ED和PE持续显著改善。缩写:ED:勃起功能障碍;IIEF-5:国际勃起功能指数调查表的五项版本;IELT:阴道内射精潜伏期;OAD:每天一次;PDE5i:磷酸二酯酶-5抑制剂;PE:早泄;PRN:出生前
{"title":"Short- and long-term follow-up results of daily 5-mg tadalafil as a treatment for erectile dysfunction and premature ejaculation","authors":"Tarek Mohamed Gharib, I. Abdel-Al, A. Elatreisy, W. Kandeel, W. El-Shaer, Abdrabuh M. Abdrabuh, El- Sayed Mohamed Salih, A. Sebaey","doi":"10.1080/2090598X.2021.2024695","DOIUrl":"https://doi.org/10.1080/2090598X.2021.2024695","url":null,"abstract":"ABSTRACT Objective To evaluate the safety and effectiveness of daily 5-mg tadalafil treatment for men who have erectile dysfunction (ED) and premature ejaculation (PE), and to assess the long-term follow-up for ED and PE improvement persistence years after the cessation of medication. Patients and Methods A prospective, single-blind, randomised study included 160 patients with ED and PE. All were evaluated using the International Index of Erectile Function (IIEF-5) questionnaire to evaluate ED and intravaginal ejaculatory latency time (IELT) for PE. Patients were subdivided into two equal groups. Group I (80 patients) treated with daily 5-mg tadalafil for 3 months, and Group II (80 patients) treated with a placebo for the same period. After 3 months of treatment and 2 years later after cessation of tadalafil, all patients were assessed for ED and PE. Results The mean (SD) IELT and IIEF-5 score pre-treatment were 37 (11.24) s and 13.2 (4.2) for Group I, while in Group II they were 35.98 (10.8) s and 13.12 (4.11), respectively. After 3 months of treatment, the mean (SD) IELT in Group I showed a highly significant improvement from 37 (11.24) s to 120.5 (47.37) s (P < 0.001) but Group II showed no significant improvement from baseline to [39.43 (13.6) s; P > 0.05]. For the IIEF-5 score, there was a highly significant improvement from baseline to 20.45 (4.5) in Group I (P < 0.001), while there was no significant difference in Group II from baseline to [15 (4.84); P > 0.05]. At 2 years after cessation of tadalafil, there was statistically significant improvement in the IELT and IIEF-5 from baseline to endpoint . Conclusion Oral daily 5-mg tadalafil was effective, tolerable, and safe treatment for patients with ED and PE. Long-term follow-up at 2 years confirmed the persistence of a significant improvement for both ED and PE. Abbreviations: ED: erectile dysfunction; IIEF-5: five-item version of the International Index of Erectile Function questionnaire; IELT: intravaginal ejaculatory latency time; OAD: once-daily; PDE5i: phosphodiesterase-5 inhibitors; PE: premature ejaculation; PRN: pro re nata","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"20 1","pages":"49 - 53"},"PeriodicalIF":1.5,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47790608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Arab Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1